New US Distribution Agreement

RNS Number : 3036P

Belluscura PLC

18 October 2021

 

Belluscura PLC

("Belluscura" or the "Company")

New US Distribution Agreement

Latest agreement ensures Company's North America distribution coverage from East to West coast

Belluscura has now exceeded initial commercial launch targets for X-PLO ₂R™ unit sales

LONDON, U.K. AND PLANO, TX, U.S. (18 October 2021).   Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology ,  announces it has signed its fifth distribution agreement in as many months, with an unnamed US-based, online partner, to distribute its maiden FDA cleared portable oxygen concentrator, X-PLO₂R™, to an even greater number of customers/potential customers within the United States.

This leading online distributor, located in Colorado, Arizona and Georgia - has already placed its first orders with Belluscura - and is a significant presence within the  portable concentrated oxygen market which has cumulatively served over 100,000 customers.

Importantly, the orders placed by the latest distribution partner mean the Company has now exceeded the initial commercial launch target for X-PLO₂R™ unit sales. This demonstrates that the management team is successfully delivering on its commercialisation strategy and also highlights the evident market anticipation for the Company's X-PLO₂R™ portable oxygen concentrator and its ability to significantly improve the current standard-of-care.

US Trade Show

This week the X-PLO₂R ™   is featured in the New Product Video showcase at Medtrade East 2021 in Atlanta.  The film includes only the newest and most innovative products at MedTrade which is the largest home medical equipment trade show and conference in the U.S.

Having now exceeded its commercial launch target for X-PLO₂R™ unit sales, which was set at the time of the AIM Admission in May 2021, the Company will update shareholders shortly as to its plans for the short to medium term.

Robert Rauker, CEO of Belluscura plc, said :  "Initial demand for the X-PLO₂R™ portable oxygen concentrator has been excellent and the addition of a fifth distributor will expand our coverage in the US.  

"Within the past five months, Belluscura has been able to put in place distribution agreements that cover the majority of North America from the East to West coast. In addition, the Company is receiving interest from overseas distributors.   We will update shareholders with expected unit deliveries for 2021 and 2022 in the near future."

About the X-PLO₂R™

The X-PLO₂R™ weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world's first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other US Food & Drug Administration ("FDA") cleared POC in its class. The X-PLO₂R™ can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO₂R™ is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.

Prior to this announcement's release, the statement contained inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR) (Market Abuse Regulation).

For further information please contact:

Belluscura plc	www.belluscura.com
Robert Rauker, Chief Executive Officer	via Walbrook PR
Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD)	Tel: [phone]
Neil Baldwin
Dowgate Capital Limited (Broker)	Tel: [phone]
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen	Mob: [phone]

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

END

 

 

AGRFLFLLILLDLIL